Literature DB >> 32150621

A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.

Matthew J Akiyama1, Daniel Lipsey1, Lilia Ganova-Raeva2, Lili T Punkova2, Linda Agyemang1, Amanda Sue2, Sumathi Ramachandran2, Yury Khudyakov2, Alain H Litwin3.   

Abstract

BACKGROUND: Understanding hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is essential for HCV elimination. We aimed to differentiate reinfections from treatment failures and to identify transmission linkages and associated factors in a cohort of PWID receiving opioid agonist therapy (OAT).
METHODS: We analyzed baseline and follow-up specimens from 150 PWID from 3 OAT clinics in the Bronx, New York. Next-generation sequencing data from the hypervariable region 1 of HCV were analyzed using Global Hepatitis Outbreak and Surveillance Technology.
RESULTS: There were 3 transmission linkages between study participants. Sustained virologic response (SVR) was not achieved in 9 participants: 7 had follow-up specimens with similar sequences to baseline, and 2 died. In 4 additional participants, SVR was achieved but the participants were viremic at later follow-up: 2 were reinfected with different strains, 1 had a late treatment failure, and 1 was transiently viremic 17 months after treatment. All transmission linkages were from the same OAT clinic and involved spousal or common-law partnerships.
CONCLUSION: This study highlights the use of next-generation sequencing as an important tool for identifying viral transmission and to help distinguish relapse and reinfection among PWID. Results reinforce the need for harm reduction interventions among couples and those who report ongoing risk factors after SVR.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HCV; IDU; OAT; PWID; hepatitis C; next generation sequencing; phylogenetic; transmission network

Mesh:

Substances:

Year:  2020        PMID: 32150621      PMCID: PMC7336560          DOI: 10.1093/infdis/jiaa100

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.

Authors:  Matthew J Akiyama; Brianna L Norton; Julia H Arnsten; Linda Agyemang; Moonseong Heo; Alain H Litwin
Journal:  Ann Intern Med       Date:  2019-04-09       Impact factor: 25.391

2.  HCV reinfection incidence among individuals treated for recent infection.

Authors:  M Martinello; J Grebely; K Petoumenos; E Gane; M Hellard; D Shaw; J Sasadeusz; T L Applegate; G J Dore; G V Matthews
Journal:  J Viral Hepat       Date:  2017-01-23       Impact factor: 3.728

Review 3.  Hepatitis C virus and liver transplantation.

Authors:  Elizabeth C Verna; Robert S Brown
Journal:  Clin Liver Dis       Date:  2006-11       Impact factor: 6.126

4.  Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.

Authors:  Y Jeong; B Jin; H W Lee; H J Park; J Y Park; D Y Kim; K-H Han; S H Ahn; S Kim
Journal:  J Viral Hepat       Date:  2018-06-13       Impact factor: 3.728

5.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

6.  Accurate Genetic Detection of Hepatitis C Virus Transmissions in Outbreak Settings.

Authors:  David S Campo; Guo-Liang Xia; Zoya Dimitrova; Yulin Lin; Joseph C Forbi; Lilia Ganova-Raeva; Lili Punkova; Sumathi Ramachandran; Hong Thai; Pavel Skums; Seth Sims; Inna Rytsareva; Gilberto Vaughan; Ha-Jung Roh; Michael A Purdy; Amanda Sue; Yury Khudyakov
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

7.  Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

Authors:  Christoph Sarrazin; Vasily Isakov; Evguenia S Svarovskaia; Charlotte Hedskog; Ross Martin; Krishna Chodavarapu; Diana M Brainard; Michael D Miller; Hongmei Mo; Jean-Michel Molina; Mark S Sulkowski
Journal:  Clin Infect Dis       Date:  2016-10-12       Impact factor: 9.079

Review 8.  Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.

Authors:  John Vizuete; Hope Hubbard; Eric Lawitz
Journal:  Clin Liver Dis       Date:  2015-07-26       Impact factor: 6.265

9.  Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs.

Authors:  Richard Pilon; Lynne Leonard; John Kim; Dominic Vallee; Emily De Rubeis; Ann M Jolly; John Wylie; Linda Pelude; Paul Sandstrom
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Next-generation sequencing reveals large connected networks of intra-host HCV variants.

Authors:  David S Campo; Zoya Dimitrova; Lilian Yamasaki; Pavel Skums; Daryl Ty Lau; Gilberto Vaughan; Joseph C Forbi; Chong-Gee Teo; Yury Khudyakov
Journal:  BMC Genomics       Date:  2014-07-14       Impact factor: 3.969

View more
  4 in total

1.  Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions.

Authors:  Noor Taweh; Esther Schlossberg; Cynthia Frank; Ank Nijhawan; Irene Kuo; Kevin Knight; Sandra A Springer
Journal:  Int J Drug Policy       Date:  2021-05-18

2.  Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.

Authors:  Moonseong Heo; Irene Pericot-Valverde; Lior Rennert; Matthew J Akiyama; Brianna L Norton; Mirinda Gormley; Linda Agyemang; Julia H Arnsten; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

3.  Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens.

Authors:  Matthew J Akiyama; Lindsey Riback; Jacqueline D Reeves; Yolanda S Lie; Linda Agyemang; Brianna L Norton; Julia H Arnsten; Alain H Litwin
Journal:  Open Forum Infect Dis       Date:  2021-09-30       Impact factor: 3.835

4.  Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.

Authors:  Claudia Minosse; Cesare E M Gruber; Martina Rueca; Chiara Taibi; Mauro Zaccarelli; Elisabetta Grilli; Marzia Montalbano; Maria R Capobianchi; Andrea Antinori; Gianpiero D'Offizi; Fiona McPhee; Anna Rosa Garbuglia
Journal:  Viruses       Date:  2021-06-16       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.